# Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant

> **NCT03386305** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Albert Einstein Healthcare Network** · enrollment: 35 (estimated)

## Conditions studied

- Post Liver Transplant

## Interventions

- **DRUG:** EnvarsusXR
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT03386305
- **Lead sponsor:** Albert Einstein Healthcare Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-13
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2021-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386305, "Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03386305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*